| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Methylated Lysine, Methyl lysine, Dimethylysine, Trimethyl lysine, N epsilon dimethyl lysine |
| Clonality | |
| Concentration | |
| Host | |
| Immunogen | Methylated KLH Conjugated |
| Product Type | |
| Reactivity | |
| Shipping | |
| Storage | |
| Target |
Methylated lysine is a key post-translational modification that plays a pivotal role in regulating gene expression, chromatin structure, and protein-protein interactions in the nervous system. Lysine residues on histone proteins can undergo mono-, di-, or tri-methylation, influencing transcriptional activation or repression depending on the site and degree of methylation. This epigenetic regulation is essential for neuronal development, synaptic plasticity, and memory formation.
In neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and Huntington’s disease, aberrant lysine methylation patterns have been linked to dysregulated gene expression and impaired neuronal function. Enzymes that catalyze lysine methylation (lysine methyltransferases) and demethylation (lysine demethylases) are increasingly recognized as contributors to disease pathogenesis. Altered activity of these enzymes can disrupt chromatin dynamics, leading to neuronal vulnerability and degeneration.
Targeting lysine methylation pathways offers a promising therapeutic strategy for modulating gene expression and restoring neuronal homeostasis. As research advances, methylated lysine serves as both a biomarker and a mechanistic link between epigenetic regulation and neurodegenerative progression.
0.2-0.5 µg/ml of SPC-158 was sufficient for detection of the methylated histone by western blot analysis using melanoma cells in TBSt.
Cite this product varies by variant:
- SPC-158D — Size: 100 ug: Methylated Lysine Antibody (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-158D, RRID: AB_2703668)
- SPC-158D-A390 — Size: 100 ug: Methylated Lysine Antibody: ATTO 390 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-158D-A390, RRID: AB_2703669)
- SPC-158D-A488 — Size: 100 ug: Methylated Lysine Antibody: ATTO 488 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-158D-A488, RRID: AB_2703670)
- SPC-158D-A594 — Size: 100 ug: Methylated Lysine Antibody: ATTO 594 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-158D-A594, RRID: AB_2703672)
- SPC-158D-APC — Size: 100 ug: Methylated Lysine Antibody: APC (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-158D-APC, RRID: AB_2703678)
- SPC-158D-FITC — Size: 100 ug: Methylated Lysine Antibody: FITC (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-158D-FITC, RRID: AB_2703679)
- SPC-158D-PCP — Size: 100 ug: Methylated Lysine Antibody: PerCP (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-158D-PCP, RRID: AB_2703681)
- SPC-158D-RPE — Size: 100 ug: Methylated Lysine Antibody: RPE (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-158D-RPE, RRID: AB_2703682)
- SPC-158S — Size: 12 ug: Methylated Lysine Antibody (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-158S, RRID: AB_2703668)
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
2. Hassig C.A. and Schreiber S.L. (1997) Curr. Opin. Chem. Biol. 1(3): 300-308.
3. Yang X.J. (2004) Bioessays 26:1076-1087.
4. Hughes R.E. (2002) Curr. Biol. 12: R141-R143.
5. Vigushin D.M. and Coombes R.C. (2004) Curr. Cancer Drug Targets 4: 205-218.
6. Chan H.M. et al. (2001) Nat. Cell Biol. 3: 667-674.
7. Martinez-Balbas M.A. et al. (2000) EMBO J. 19: 662-671.